May 31, 2016 1:59 AM ET

Pharmaceuticals

Company Overview of Sunovion Pharmaceuticals Inc.

Company Overview

Sunovion Pharmaceuticals Inc. develops and markets pharmaceutical products. The company offers products for central nervous system disorders, such as insomnia, schizophrenia, bipolar depression, and epilepsy disorders; attention deficit hyperactivity and binge-eating disorders; and respiratory conditions, including asthma, allergy, and chronic obstructive pulmonary disease areas. Sunovion Pharmaceuticals Inc. was formerly known as Sepracor Inc. and changed its name to Sunovion Pharmaceuticals Inc. in October 2010. The company was founded in 1984 and is headquartered in Marlborough, Massachusetts. As of October 20, 2009, Sunovion Pharmaceuticals Inc. operates as a subsidiary of Dainippon Sumi...

84 Waterford Drive

Marlborough, MA 01752

United States

Founded in 1984

2,400 Employees

Phone:

508-481-6700

Fax:

508-481-7683

Key Executives for Sunovion Pharmaceuticals Inc.

Chairman and Chief Executive Officer
Chief Financial Officer and Senior Vice President
Chief Administrative Officer and Executive Vice President
Chief Compliance & Ethics Officer and Senior Vice President
Chief Medical Officer, Executive Vice President and Head of Global Clinical Development
Compensation as of Fiscal Year 2015.

Sunovion Pharmaceuticals Inc. Key Developments

Sunovion Pharmaceuticals Inc. Announces the Results of Brovana® (arformoterol tartrate) Inhalation Solution

Sunovion Pharmaceuticals Inc. announced the results of a post-hoc analysis of a long-term safety study evaluating Brovana® (arformoterol tartrate) Inhalation Solution in people with moderate-to-severe chronic obstructive pulmonary disease (COPD) at the 2016 American Thoracic Society International Conference (ATS 2016), taking place May 13-18, 2016 in San Francisco, Calif. Results from this analysis reinforce the use of BROVANA in COPD, as measured by COPD exacerbation-related hospitalizations compared to those treated with placebo. BROVANA is a twice-daily nebulized long-acting beta2-agonist (LABA) approved by the U.S. Food and Drug Administration (FDA) for the long-term maintenance treatment of bronchoconstriction in people with COPD, including chronic bronchitis and emphysema. Data for this post hoc analysis came from a multicenter, randomized, double-blind, 52-week safety trial evaluating BROVANA versus placebo in patients with moderate-to-severe COPD. Data on COPD exacerbation and associated hospitalization events were collected in the study. Post-hoc analyses of these data demonstrated that patients receiving BROVANA exhibited lower annualized COPD exacerbation-related hospitalization rates compared with patients receiving placebo. The BROVANA group also reported a greater reduction in hospitalization risk relative to placebo, and these results were more pronounced in a subset of patients who were responders on the St. George’s Respiratory Questionnaire (SGRQ) (i.e., patients who achieved a minimum 4-point improvement in SGRQ total score at study end). The SGRQ is an index designed to measure and quantify health-related health status in patients with chronic airflow limitation that has been shown to correlate well with established measures of symptom level, disease activity and disability.1 For the intent-to-treat population, the adjusted annualized hospitalization rate was significantly reduced with BROVANA compared with placebo (relative risk = 0.60 [95% confidence interval (CI) = 0.41, 0.87; P = 0.007]). For those patients who were SGRQ responders, the adjusted relative risk was the lowest at 0.34 (95% CI = 0.12, 0.99; P = 0.048); SGRQ non-responders had an adjusted relative risk of 0.81 (95% CI = 0.39, 1.67; P = 0.573).

Sunovion Pharmaceuticals Inc. Announces Positive Results from Phase 3 Clinical Trial Program for SUN-101

Sunovion Pharmaceuticals Inc. announced positive results from the Phase 3 clinical trial program for SUN-101 (glycopyrrolate), a nebulized long-acting muscarinic antagonist (LAMA), delivered via PARI’s innovative investigational eFlow® nebulizer system (SUN-101/eFlow®), for people with moderate-to-very severe chronic obstructive pulmonary disease (COPD). The two clinical trials met their primary endpoints with a statistically significant change from baseline in trough forced expiratory volume in one second (FEV1) at Week 12 for both the 50 mcg and 25 mcg dose groups versus placebo. SUN-101/eFlow® also was found to be well-tolerated as a twice-daily maintenance treatment of bronchoconstriction in patients with COPD. SUN-101 (glycopyrrolate) is a long-acting muscarinic antagonist (LAMA) bronchodilator delivered via the innovative, proprietary closed investigational eFlow® nebulizer system. SUN-101/eFlow® is currently in development as a nebulized treatment for patients with moderate-to-very severe chronic obstructive pulmonary disease (COPD). The investigational combined product, consisting of SUN-101 and the closed eFlow® nebulizer system which has been optimized for SUN-101 delivery, has not been approved by the U.S. Food and Drug Administration (FDA) for the treatment of COPD.

PGI Drug Discovery LLC Announces Drug Discovery Collaboration with Sunovion Pharmaceuticals Inc

PGI Drug Discovery LLC announced that a compound identified through its drug discovery collaboration with Sunovion Pharmaceuticals Inc. has achieved a milestone. The compound, SEP-856, is a potential antipsychotic agent with a novel mechanism of action being investigated as a possible treatment for patients with schizophrenia. The preclinical models for SEP-856 suggest that it may have the potential to treat the negative symptoms of schizophrenia.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Sunovion Pharmaceuticals Inc., please visit www.sunovion.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.